Report Explores Future of Opioid Abuse-Resistant Formulations - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Report Explores Future of Opioid Abuse-Resistant Formulations



A new report from GBI Research reviews the current opioid-product market, analyzes the development pipeline, and reviews industry merger, acquisition, and licensing deals to develop a picture of the market through 2018. The increase in opioid use has led to an increase in abuse and consequently to increasing concern from doctors and regulators. As a result, approved drugs are differentiated increasingly by abuse-resistant technologies.

Many companies are working to develop abuse-resistant formulations of extended-release (ER) opioid analgesics, notes GBI Research. Most recent marketing approvals for ER opioids in the US have included risk evaluation and mitigation strategies that require license holders to provide physician training and raise patient awareness of opioid abuse. In many cases, post-marketing studies are required to examine the efficacy of abuse-resistant formulations. Initial post-marketing data reports for Embeda, which was launched in the US in 2009, are positive.

The current opioids market has a broad and highly diversified product profile, reports GBI Research. The developmental pipeline is small, however, and the market is relatively stagnant. Competition among abuse-resistant products is expected to be the driving factor in this market.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
20%
Attracting a skilled workforce
28%
Obtaining/maintaining adequate financing
12%
Regulatory compliance
40%
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatcchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Obama Administration Halts Attack on Medicare Drug Plans

Click here